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Abstract 
Candida is currently the most implicated pathogenic fungal species recognized as the major cause of a 
variety of human infections all over the world. This study investigated species distribution, enzymatic 
activities, and antifungal resistance profiles of human and animal Candida species. Clinical Candida 
species (n=220) were isolated from urine, high vaginal swab (HVS) and blood while Candida species 
(n=128) were isolated from rectal swab, ear swab, blood, feces, and milk in animals: goat, sheep, cattle, 
pig and chicken. The identification of the species was performed using standard methods. Enzymatic 
activity was screened using plate methods. Susceptibility testing was carried out using disk diffusion 
and broth microdilution methods. A statistically significant difference (P=0.031) was observed in the 
distribution of Candida spp. recovered from humans and animals. The Pz values of human Candida 
species for proteinase, hemolysin, lipase and phospholipase were 0.65±0.97, 0.61±0.81, 0.59±0.47 and 
0.76±0.74 respectively while that of Candida species recovered from animal were 0.67±0.13, 0.61±0.95, 
0.62±0.67 and 0.69±0.70 respectively. No statistically significant difference (P>0.05) in the in vitro 
enzymatic activity was observed between the two groups. High azole-resistance rate was observed. 
Resistance was higher among human Candida isolates compared to animal isolates although the 
difference was not considered statistically significant (p = 0.519). Our findings suggest that the 
enzymatic activity (virulence potential) and resistance patterns are similar in the two groups 
investigated. This study underscores the importance of animals especially pets and their products as 
potential sources/reservoirs of pathogenic and multi-azole resistant Candida species in Nigeria. 
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Candidiasis is now considered the third to fourth 
most frequent nosocomial infection in the US and 
worldwide, behind bacterial infection caused by 
Clostridium difficile, Neisseria gonorrhea and 
Enterobacteriaceae (Lamoth et al., 2018). 
Candida spp., the causative agent of candidiasis 
is an aerobic, diploid, and dimorphic yeast that 
belongs to ascomycetes class of fungi. 
Ascomycetes are commensals of domestic 
animals and wildlife and have frequently been 
isolated from rheas, dogs, horses, goats, sheep 
and sirenians (Brilhante et al., 2013; Cordeiro et 
al., 2013; Cordeiro et al., 2015). Candida is also 
part of the microbiota of the human body. They 
colonize various anatomical sites such as the oral 
cavity, digestive tract, vagina, and skin. 
Hormansdorfer and Bauer (2000), reported that 
domestic animals such as horses, cattle, cats, 
pigs, and dogs as well as birds are susceptible to 
candidiasis. Therefore, Candida may arise as an 
important health issue in both humans and 
animals. Besides the environmental impact, 
animals can serve as sources of infection for 
humans, and humans can infect animals and vice 
versa (Rozanski et al., 2017). Recent findings 
show an increase in the rate of infections 
associated with Candida species (Alkharashi et 
al., 2019). Furthermore, the resistance of 
Candida species to antifungal drugs especially 
the azoles are a public health concern. The 
azoles are widely used because of their few side 
effects and easy oral bioavailability. They are 
fungistatic, meaning that they do not kill the 
fungal cells, rather they merely stop it from 
growing. The downside to this is that it gives the 
organism time to develop resistance. Although 
some Candida species have natural resistance 
even without prior exposure to antifungals 
agents, it is also possible and common for strains 
that are initially susceptible to develop resistance. 
There have also been some insinuations that 
animals are source of resistant Candida species 
(Brilhante et al., 2013). 
It is not surprising that many studies have 
recently focused on Candida pathogenesis, 
aimed at developing better approaches to the 
management of candidiasis. The virulent factors 
have attracted utmost interest. The extracellular 
hydrolytic enzymes happen to be the major 
virulence factor necessary for Candida infection 
establishment. The enzymes most commonly 
implicated in Candida pathogenesis process 
include the proteinase, phospholipase, lipase and 
hemolysin. Increase in the production and activity 
of the hydrolytic enzymes highly influence the 
pathogenic potential of Candida species 
(Maheronnaghsh et al., 2019). There have been 
some insinuations that animals could serve as 
vectors for transmission of infectious diseases or 
as reservoirs of human pathogenic and antifungal 
resistant Candida species and may pose a risk 
most especially for immunocompromised 
patients (Brilhante et al., 2013). Over the years, 
researchers have been paying more attention to 
human Candida infections.  While this is 
understandable, it has created some vacuum in 
studies related to animals. Few studies, however, 
have shown that animals harbor potentially 
pathogenic and antifungal resistant Candida 
species (Cordeiro et al., 2015; Osman et al., 
2019). 
This study, therefore, assessed and compared 
Candida spp. distribution, extracellular hydrolytic 
enzyme activity (virulence factors) and antifungal 
resistant profile among Candida isolates 
recovered from human and animal samples in 
Enugu State, Nigeria. The key objectives of the 
study were to ascertain the prevalence and 
distribution of Candida species in humans and 
animals, ascertain if healthy animals and their 
droppings harbor potentially pathogenic Candida 
species including antifungal resistant strains and 
elucidate the extent and similarity in enzyme 
production and resistance profile between human 
and animal Candida spp. 
MATERIALS AND METHODS 
 
Sample collection and identification 
Human clinical Candida isolates (n=220) were 
isolated from samples collected from patients 
who visited three different hospitals (Bishop 
Shanaham Hospital, University of Nigeria 
Medical Center and Enugu Ezike General 
Hospital) during the study period. The Candida 
species were recovered from the following body 
sites after obtaining informed consent: high 
vaginal swab (HVS) (n=38), urine (n=129), blood 
(n=53). Candida species were also isolated from 
animals (n=128) presumed to be healthy. These 
animals were displayed in an abattoir for 
slaughtering before selling to the customers. All 
animal samples were collected before the 
slaughtering of the animal. Moreover, animal 
samples were also collected from an animal farm 
located at the University of Nigeria, Nsukka. The 
isolates were obtained from sheep, goat, cattle, 
  
Bio-Research Vol.17 No.1 pp.1044A-1055A (2019) 
1046A 
 
pig, and chicken.  The sample types include rectal 
swab (n=76), blood (n=30), feces (n=13), cow 
milk (n=8) and ear swab (n=1). All samples were 
sourced within Enugu State, Nigeria. The medical 
conditions of the sampled subjects for any signs 
of Candida infections (example fungaemia) were 
not pursued further after samples were collected. 
All the approved standard procedures for use in 
human and animal experiments were followed in 
the study. The samples were cultured on 
Sabouraud dextrose agar (HiMedia, Mumbai, 
India) supplemented with 1% chloramphenicol 
(0.05g/L) and then incubated at 37⁰C for 24-48 hr. 
Identification of Candida spp. was based on 
colony morphology, germ tube test, and growth 
characteristics on CHROMagar Candida (Oxoid, 
Basingstoke, UK) and the different Candida 
species were differentiated based on the color of 
the colonies on CHROMagar Candida as 
previously described (Nadeem et al., 2010). 
Susceptibility testing using antifungal disks 
Antifungal susceptibility of 194 Candida isolates 
recovered from the samples was ascertained by 
testing the isolates against the following drugs 
(Himedia, Pennsylvania, USA): fluconazole 
(25µg), voriconazole (1µg), itraconazole (30µg), 
ketoconazole (30µg), clotrimazole (10µg) and 
nystatin (50IU).  The disk diffusion technique was 
performed on Mueller-Hinton Agar (MHA) plates 
supplemented with 2% glucose with 0.5mcg/ml 
methylene blue dye medium. The diameter of the 
zone of inhibition was measured and interpreted 
according to the Clinical and Laboratory 
Standards Institute (CLSI) approved protocol, 
CLSI document M44-A2 (CLSI, 2009).  
 
Minimum inhibitory concentration (MIC) 
The MIC was determined using broth 
microdilution method and according to the CLSI 
M27- A3 broth microdilution approved standard 
(CLSI, 2008). The tested drugs for the MIC were 
fluconazole, itraconazole, and nystatin. The MIC 
of fluconazole and itraconazole was regarded as 
the lowest antifungal concentration with 
substantially lower (50% reduction) turbidity 
compared to the growth in the drug free tube. The 
MIC of nystatin was defined as the lowest drug 
concentration which resulted in complete 




Phospholipase and lipase activity was 
determined using the method described by Price 
et al. (1982). Proteinase activity was determined 
using bovine serum albumin agar as reported by 
Junior et al. (2011), while hemolytic activity was 
determined using the method described by Luo et 
al. (2001). The precipitation zone (Pz value) for 
all the enzymes evaluated was calculated and 
interpreted as already established by Price et al. 
(1982) using the formula:     
𝑃𝑧 =  
𝐶𝑜𝑙𝑜𝑛𝑦 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟
𝐶𝑜𝑙𝑜𝑛𝑦 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 + 𝑍𝑜𝑛𝑒 𝑜𝑓 𝑃𝑟𝑒𝑐𝑖𝑝𝑖𝑡𝑎𝑡𝑖𝑜𝑛
 
Statistical analysis 
Chi-square (χ2) test was carried out on the 
obtained data to determine whether the 
differences observed in the prevalence and 
distribution of Candida spp. among the different 
groups studied were statistically significant. One-
way analysis of variance (ANOVA) and Tukey’s 
multiple comparisons post-hoc test was used to 
assess and compare the differences in enzymatic 
activity and resistant pattern. Results with P< 
0.05 was considered significant. The statistical 
analysis was done using the SPSS software 
version 23.0 (SPSS Inc., Chicago, IL, USA). The 
single isolate recovered from animal ear swab 
was not included in the analysis because it was 
not representative. All experiment was repeated 
two times on different days and the average of the 
values ± standard deviation was calculated. 
RESULTS 
Candida species distribution 
Five Candida species (C. albicans, C. glabrata, 
C. tropicalis, C. krusei and C. parapsilosis) were 
recovered and identified from both human and 
animal samples. Of the entire human isolates 
(n=220), C. albicans accounted for 96 (43.6%) 
while non-albicans accounted for 124 (56.4%) 
(Table 1). Among animal isolates (n=128), C. 
albicans account for 41(32%) while non-albicans 
account for 87(68%). C. parapsilosis was the 
most prevalent, accounting for 25 (19.5%) of the 
entire animal samples followed by C. glabrata, 18 
(14.1%) (Table 2). C. albicans was the most 
frequently isolated species in both human and 
animal samples (Table 3). However, when non-
albicans are combined together, they represent a 
greater percentage than the C. albicans 
recovered from both human and animal isolates. 
Non- albicans Candida were mostly isolated from 
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animals than from humans where they represent 
68% of the entire animal samples compared to 
56% recovered from humans. The overall 
prevalence of C. albicans and non-albicans in the 
study is 39.4% and 60.6% respectively. 
Moreover, there was a statistically significant 
difference (P=0.031) in the occurrence of 
Candida spp. between humans and animals. 
Enzymatic activities in human and animal 
Candida species 
Table 4 illustrates the distribution of human and 
animal Candida species showing different 
virulence attributes while Figure 1A shows the 
percentage of different clinical Candida isolates 
producing extracellular enzymes. All the Candida 
species (100%) recovered from human blood 
were hemolysin and lipase producers. The blood 
Candida isolates also displayed a higher 
phospholipase activity (71.4%) than the rest of 
the samples. Overall, the clinical samples 
showed very strong enzymatic activity. Figure 1B 
shows the percentage of Candida isolates from 
different animal samples with extracellular 
enzyme production. Candida isolates from cow 
milk showed 100% lipase activity while the rest of 
the isolates from rectal swab, blood and feces 
also displayed very strong enzyme activity as 
observed in clinical human samples. One notable 
observation was that over eighty percent of the 
recovered isolates from animal blood were 
positive for all the studied enzymes. Comparing 
the percentage enzymatic activities between 
human and animal isolates, it was observed that 
out of 158 human and 98 animal isolates 
screened for proteinase activity, 84.2% and 
83.7% showed positive activity, respectively. 
88.2% and 89.6% of human (n=152) and animal 
(n=96) isolates respectively were positive for 
hemolysin activity. For lipase activity, 83.2% and 
80% of human and animal isolates were 
respectively positive while 74.3% and 52.3% of 
human (n=91) and animal (n=65) isolates 
displayed phospholipase activity respectively 
(Figure 1C). Majority of the human and animal 
isolates had very low Pz values indicating strong 
enzymatic activity except in phospholipase where 
52.7% of human and 47.7% of animal had a Pz 
value of 1. 
Resistance profile in human and animal 
Candida species 
 
A high resistance rate was noted in this study. 
Table 5 shows the in vitro antifungal susceptibility 
profile of the recovered Candida species. All the 
recovered isolates showed higher susceptibility 
to nystatin than all the azoles as seen in the 
zones of inhibitions. The minimum inhibitory 
concentration (MIC) values for some of the 
recovered Candida isolates are shown in Table 6. 
Figure 2A shows the resistance profile of isolates 
from clinical samples while Figure 2B shows the 
resistance profile of isolates from animal 
samples. Resistance was more prominent among 
Candida isolates recovered from the blood of 
animals. Out of 14 Candida isolates recovered 
from blood, 13 (92.9%) were resistant to 
fluconazole only while 12 (85.7%) showed 
resistance to clotrimazole, voriconazole, 
itraconazole, and ketoconazole. Figure 2C shows 
the percentage resistance comparison in human 
and animal Candida species. Overall, resistance 
was higher in human than in animal isolates. 
However, the difference was not considered 
statistically significant (P > 0.05). 
Discussion  
Candida species are part of the natural 
microbiota of humans and animals. They are the 
major cause of fungal infections in humans and 
animals. A substantial number of the recovered 
isolates were from urine and blood, which 
indicate that other than bacteria, pathogenic fungi 
(Candida spp.) are also responsible for a large 
number of urinary and bloodstream infections 
frequently reported in hospitals. Findings from our 
investigation agree with recent epidemiological 
patterns which suggest a shifting trend from the 
albicans to the non-albicans. Candida albicans 
was more predominant in human samples. 
Similar findings have been reported in Nigeria 
(Nweze and Ogbonnaya, 2011). C. albicans was 
more frequently recovered from the blood of 
animals (pig and sheep) (43.3%) and were also 
the most common Candida spp. in the whole 
animal samples. However, when comparing the 
C. albicans and non-albicans recovered from 
both human and animal samples, the non-
albicans Candida species were significantly 
(P<0.05) more than Candida albicans. A 
predominance of non-albicans Candida species 
(68%) was observed in animal samples screened 
in the study and C. parapsilosis was the most 
frequently occurring.  This is contrary to a report 
by Kemoi et al., (2013) who reported C. lusitaniae 
as the most common Candida spp. 
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Table 1: Distribution of Candida species in different human samples 
 
                                                                Candida species Total 
C. albicans C. glabrata C. tropicalis C. krusei C. parapsilosis Others  
Human Urine 47 (36.4%) 28 (21.7%) 14 (10.9%) 16 (12.4%) 10 (7.8%) 14 (10.9%) 129 
HVS 24 (63.2%) 6 (15.8%) 0 (0.0%) 2 (5.3%) 4 (10.5%) 2 (5.3%) 38 
Blood 25 (47.2%) 4 (7.5%) 3 (5.7%) 5 (9.4%) 5 (9.4%) 11 (20.8%) 53 
Total 96 (43.6%) 38 (17.3%) 17 (7.7%) 23 (10.5%) 19 (8.6%) 27 (12.3%) 220 









                                                Candida species Total 
C. albicans C. glabrata C. tropicalis C. krusei C.parapsilosis Others 
Animal (Rectal swab) 25 (32.9%) 10 (13.2%) 11 (14.5%) 6 (7.9%) 15 (19.7%) 9 (11.8%) 76 
 (Ear swab) 0 (0.0%) 1 (100.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 
 (Blood) 13 (43.3%) 5 (16.7%) 0 (0.0%) 5 (16.7%) 2 (6.7%) 5 (16.7%) 30 
(Faeces) 3 (23.1%) 1 (7.7%) 4 (30.8%) 0 (0.0%) 3 (23.1%) 2 (15.4%) 13 
(Milk) 0 (0.0%) 1 (12.5%) 0 (0.0%) 2 (25.0%) 5 (62.5%) 0 (0.0%) 8 













                                                           Candida species Total 
C. albicans C. glabrata C. tropicalis C. krusei C. parapsilosis Others  
Samples Human 96 (43.6%) 38 (17.3%) 17 (7.7%) 23 (10.5%) 19 (8.6%) 27 (12.3%) 220 
Animal 41 (32.0%) 18 (14.1%) 15 (11.7%) 13 (10.2%) 25 (19.5%) 16 (12.5%) 128 
Total 137 (39.4%) 56 (16.1%) 32 (9.2%) 36 (10.3%) 44 (12.6%) 43 (12.4%) 348 
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Human                                                                                   Animal  
 n Mean ± SD Range  n Mean ± SD Range P value 
Proteinase C. albicans  73 0.59±0.21 0.31-1  37 0.54±0.18 0.34-1 0.797 
C. glabrata  30 0.72±0.24 0.31-1  18 0.71±0.26 0.39-1  
C. tropicalis  13 0.51±0.11 0.38-0.73  10 0.90±0.10 0.81-1  
C. krusei  13 0.64±0.22 0.38-1  9 0.67±0.25 0.37-1  
C. parapsilosis  14 0.79±0.21 0.46-1  12 0.58±0.23 0.42-1  
Others  15 0.66±0.21 0.43-1  12 0.60±0.20 0.38-1  
Hemolysin C. albicans  70 0.63±0.18 0.35-1  34 0.61±0.18 0.42-1 0.873 
C. glabrata  29 0.76±0.21 0.51-1  19 0.61±.18 0.43-1  
C. tropicalis  12 0.61±0.16 0.40-1  10 0.77±0.11 0.65-0.85  
C. krusei  12 0.52±0.12 0.32-0.69  9 0.48±0.13 0.40-0.71  
C. parapsilosis  14 0.58±0.10 0.45-0.73  12 0.62±0.15 0.40-0.88  
Others  15 0.59±0.20 0.41-1  12 0.55±0.16 0.35-0.87  
Lipase C. albicans  71 0.57±0.22 0.33-1  34 0.57±0.19 0.40-1 0.512 
C. glabrata  29 0.66±0.26 0.31-1  17 0.67±0.26 0.41-1  
C. tropicalis  13 0.58±0.19 0.41-1  11 0.60±0.17 0.50-0.80  
 C. krusei  13 0.53±0.20 0.37-1  9 0.60±0.23 0.39-1  
C. parapsilosis  14 0.63±.27 0.37-1  12 0.53±0.18 0.34-0.80  
Others  15 0.59±0.22 0.35-1  12 0.71±0.26 0.39-1  
Phospholipase C. albicans  37 0.76±0.25 0.32-1  24 0.60±0.21 0.38-1 0.117 
C. glabrata  17 0.78±0.20 0.53-1  14 0.70±0.22 0.37-1  
C. tropicalis  8 0.90±0.21 0.45-1  5 0.76±0.22 0.55-1  
C. krusei  7 0.76±0.14 0.62-1  7 0.68±0.30 0.41-1  
C. parapsilosis  11 0.70±0.19 0.45-1  6 0.63±0.15 0.37-0.75  
Others  11 0.69±0.29 0.38-1  9 0.78±0.29 0.32-1  
Key: n=number of tested Candida specie; SD=standard deviation; Pz: precipitation zone (mm); Pz=<0.69, very strong; Pz=0.70-0.79, strong; Pz=0.80-0.89, low; Pz=0.90-0.99, very low; Pz=1, negative; 
Values with P<0.05 were considered statistically significant 
  














































    
Figure 1: Percentage comparison of the enzyme production. A= Percentage of different human clinical Candida isolates with extracellular enzyme 
production; B= Percentage of different animals Candida isolates with extracellular enzyme production; C= Percentage comparison of the enzyme 
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Table 5: In vitro antifungal susceptibility profile of the recovered Candida species 
KEY: R: Number of resistant Candida isolates; IZD: inhibition zone diameter (mm); SD: standard deviation 
 
             Table 6: Minimum inhibitory concentration (MIC) of the some recovered Candida isolates 
 
  FLU  ITR  NYS  
Sample Candida spp (n) MIC range  GM MIC range GM MIC range GM 
Human C. albicans (10) 1-64 19.69 NR NR 0.12-8 0.80 
 C. glabrata (3) 32-64 40.32 1-2 1.59 NR NR 
 C. tropicalis (3) 4-64 12.70 0.12-2 1.00 2-4 2.520 
 C. krusei (3) 4-64 12.70 0.5-2 1.00 0.5-2 0.79 
 C. parapsilosis(3) 0.5-64 10.08 0.12-1 0.49 NR NR 
Animal C. albicans (10) 0.12-64 9.15 0.12-8 0.87 0.12-8 0.80 
 C. glabrata (3) 32-64 40.32 1-2 1.26 0.12-0.25 0.15 
 C. tropicalis (3) 1-64 4 0.12-2 0.49 2 2 
 C. krusei (3) 8-64 25.40 0.25-1 0.63 1 1 
 C. parapsilosis(3) 1-4 9.35 0.5-1 0.79 NR NR 
KEY: MIC, minimum inhibitory concentration (µg/ml); GM, geometric mean (µg/ml);                                                                                                                                                                                                             
FLU- fluconazole; ITR- itraconazole; NYS- nystatin; NR- no result                              
 
 













C. albicans (n=92) 88 1.22±5.868 86 1.11±4.391 87 1.51±6.367 84 1.66±5.622 88 1.34±5.717 15 12.59±4.328 
C. glabrata (n=35) 21 10.74±13.349 27 4.89±9.330 18 12.77±14.128 26 5.34±8.931 26 7.89±13.099 3 16.14±5.600 
C. tropicalis (n=12) 9 6.75±12.308 9 4.42±8.447 9 7.50±13.774 9 4.83±8.851 9 6.67±12.287 2 14.33±4.905 
C. krusei (n=15) 13 2.33±6.298 14 1.33±5.164 11 6.73±11.949 9 7.60±9.898 14 1.40±5.422 6 10.07±8.722 
C. parapsilosis(n=22) 12 11.45±12.701 15 5.36±8.104 12 13.95±16.058 14 7.18±9.272 14 8.77±12.000 5 14.00±5.521 
Others (n=18) 16 2.50±7.278 16 1.94±5.724 16 3.50±8.753 13 5.22±8.948 16 3.06±7.368 7 11.11±5.989 
  






         
     
   
Figure 2: Resistance profiles of Candida spp from human and animal samples. FLU (fluconazole, 25µg), CLO (clotrimazole, 10µg), VOR 
(voriconazole, 1µg), ITR (itraconzaole, 30µg), KET (ketoconazole, 30µg), NYS (nystatin, 50 IU). A=percentage resistance profile of the different 
human clinical isolates; B=percentage resistance profile of the different animal Candida isolates; C=percentage comparison between the 
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isolated from animal samples. Our results are 
however similar to the findings by El-Diasty et 
al. (2017) who isolated and characterized 
different yeast cells from poultry 
slaughterhouses and workers. According to the 
study, C. albicans was the most commonly 
isolated species followed by C. Lusitaniae, C. 
parapsilosis, and C. tropicalis. The variation in 
species distribution with other studies might be 
due to differences in the sample types 
screened, geographical location, and the 
differences in the identification methods used. 
Although the frequency of occurrence of 
Candida spp. (according to the different 
localities where the samples were collected) 
was not reported, it is reasonable to believe that 
Candida spp. is widely distributed in the 
different localities. 
The production of extracellular enzymes is one 
of the major parameters to distinguish virulent 
invasive strains from non-invasive strains. 
These enzymes are crucial for infection 
establishment (Mba and Nweze, 2020). In the 
present study, approximately 89% of C. 
albicans and 82% of NACs were proteinase 
producers. Several other researchers have 
reported similar findings (Pandey et al., 2018; 
Jasim et al., 2016). Very low Pz values and a 
greater number of proteinase positive isolates 
were largely observed from human and animal 
isolates recovered from blood samples, thus 
making the blood Candida isolates the most 
potent proteinase producers. The environment 
(blood) may likely have had a profound 
influence on the pathogenic potential of the 
isolated Candida species in this study.  The 
high production of proteinase by non-albicans 
Candida isolates recovered from both animals 
and humans in this study suggest that more 
attention needs to be given to non-albicans 
Candida species as a result of their emerging 
clinical relevance.  
More than 80% of all our isolates from humans 
and animals were hemolysin and lipase 
producers.  Other researchers have also 
documented high hemolysin and lipase 
production among Candida species (Pandey et 
al., 2018; Akinjogunla et al., 2018). 
Phospholipase activity was noted in 64% of the 
Candida albicans isolates. This agrees with a 
study by Butola et al. (2015) who reported 
phospholipase activity in 60% of C. albicans 
while only 37% of the non-albicans Candida 
spp showed phospholipase activity. Brilhante et 
al. (2013) and Cordeiro et al. (2015) showed 
that Candida species isolated from animals 
show resistance to azoles and also produce 
extracellular enzymes. In our investigation, 
Candida species recovered from blood 
samples in humans and animals were the most 
potent producers of phospholipase. Most non-
albicans isolates in our study showed low 
phospholipase activity. The low phospholipase 
activity in the majority of the non-albicans 
Candida species in this study may suggest that 
the enzyme is probably not a significant 
virulence attribute for these species. 
The differences in the enzymatic activity both in 
human and animal samples suggests that the 
potential for Candida species to produce 
extracellular enzyme depends on the sample 
source. Generally, the virulence factors 
produced by Candida spp. may vary depending 
on the stage, type, site of infection, and even 
the host immune nature. Also, anatomically 
distinct sites affect the pathogenic potential of 
Candida spp. Therefore, the variability in 
enzymatic activity reported here might be due 
to the biological differences among the isolates 
recovered from different sample sources/sites. 
Since the expression and induction of 
extracellular hydrolytic enzymes correlate with 
pathogenicity and infection initiation (Mba and 
Nweze 2020), the presence of these enzymes 
even among healthy animals, most especially 
animal blood and cow milk might be a source of 
worry. Its implication in human health, 
especially among consumers of these animals 
and their products and even among those 
exposed to these animals cannot be 
overemphasized. Although both the humans 
and animals were not screened for any 
systemic fungal infection before sample 
collection, there is a possibility that some of 
them that showed positive Candida growth 
(especially in the blood samples) have systemic 
Candida infection. Overall, our data showed 
that Candida isolates from animals and humans 
exhibit similar and equal virulence attributes. 
The high azole resistance rate recorded in our 
study agrees with previous findings by Owotade 
et al. (2016) who reported multi-azole 
resistance in among Candida species. The in-
vitro antifungal testing revealed that 
susceptibility was higher among Candida spp. 
subjected to the polyene (nystatin) than the 
azoles. Also, Candida tropicalis recovered from 
animal samples showed a high resistant rate to 
the azole antifungal drugs. This corroborates 
the findings of Cordeiro et al. (2015), who 
reported that C. tropicalis isolates from healthy 
animals showed a high rate of resistance to 
azoles. Similar reports have also been noted by 
other researchers (Brilhante et al., 2013). 
Currently, a lot of antibiotics are used as regular 
supplements for growth promotion in animals. 
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This practice exposes a large number of 
animals, irrespective of their health status to a 
sub-therapeutic concentration of antimicrobials, 
thereby increasing the likely occurrence of 
resistance. Therefore, frequent exposure to 
antibiotic therapy, immunosuppression, and 
increased exposure of humans and animals to 
environmental fungi are some of the 
predisposing factors. Since the prior treatment 
history of these animals with antifungals drugs 
was not investigated, we want to presume that 
the high resistance to azoles observed in this 
study may be due to selective pressures 
induced by the exposure to azole products used 
in clinical practice or agriculture. It could also be 
due to the presence of these compounds in the 
feed, water, and fruit consumed by these 
animals. The high rate of azole resistance 
among Candida spp recovered from humans 
could be due to the widespread use of azoles in 
the therapeutic and prophylactic management 
of candidiasis and other fungal infections. Even 
intrinsic resistance shown by various yeasts to 
the antifungal agents cannot be overlooked. It 
is also possible that drug-resistant strains in 
animals may have originated from humans.  
Conclusion 
This study showed that there is a difference in 
Candida species distribution in humans and 
animals, as the non-albicans Candida spp. 
appear to be more frequently isolated from 
animals. Sequel to the high extracellular 
enzyme production and high level of azole 
resistance observed in this study, it is safe to 
conclude that there is a strong correlation 
between the extracellular production of 
enzymes and azole antifungal resistance. 
Furthermore, this study showed that Candida 
isolates from animals and humans exhibit 
similar virulence and antifungal resistant 
attributes. We, therefore, conclude that healthy 
animals and their droppings harbor potentially 
pathogenic Candida species, including multi-
azole-resistant strains that are capable of 
secreting extracellular hydrolytic enzymes.  
Humans are at risk of contracting candidiasis 
when they eat or come in contact with the 
animals and their products. However, a 
throughput molecular genotyping investigation 
is needed to confidently justify this claim.
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